

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
25 January 2024 (25.01.2024)



(10) International Publication Number
WO 2024/020127 A1

(51) International Patent Classification:

C07F 9/6561 (2006.01) A61K 31/675 (2006.01)
A61P 31/20 (2006.01) A61K 45/06 (2006.01)
C07F 9/02 (2006.01)

(21) International Application Number:

PCT/US2023/028218

(22) International Filing Date:

20 July 2023 (20.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/391,283	21 July 2022 (21.07.2022)	US
63/400,661	24 August 2022 (24.08.2022)	US
63/412,143	30 September 2022 (30.09.2022)	US
202211206517.7	30 September 2022 (30.09.2022)	CN

(71) Applicant: ANTIVA BIOSCIENCES, INC. [US/US];

280 Old Country Road, #257, Brisbane, CA 94005 (US).

(72) Inventors: ALDOUS, Barry; c/o Antiva Biosciences,

Inc., 280 Old Country Road, #257, Brisbane, CA 94005 (US). GADIRAJU, Ramakrishna; c/o Antiva Biosciences, Inc., 280 Old Country Road, #257, Brisbane, CA 94005 (US). WALTER, Sarah; c/o Antiva Biosciences, Inc.,

280 Old Country Road, #257, Brisbane, CA 94005 (US). DANIELS, Oranee; c/o Antiva Biosciences, Inc., 280 Old Country Road, #257, Brisbane, CA 94005 (US). MADERIS, Gail; c/o Antiva Biosciences, Inc., 280 Old Country Road, #257, Brisbane, CA 94005 (US). ARGADE, Ankush; c/o Antiva Biosciences, Inc., 280 Old Country Road, #257, Brisbane, CA 94005 (US). MAHALINGAM, Ravichandran; C/o Antiva Biosciences, Inc., 280 Old Country Road, #257, Brisbane, CA 94005 (US). ZHAO, Zhengle; c/o WuXi Apptec Co., Ltd., 90 Delin Road Waigaoqiao, Free Trade Zone, Shanghai 200131 (CN). QIN, Zhaoyang; c/o WuXi Apptec Co., Ltd., 90 Delin Road Waigaoqiao, Free Trade Zone, Shanghai 200131 (CN). JIANG, Siyi; c/o WuXi Apptec Co., Ltd., 90 Delin Road Waigaoqiao, Free Trade Zone, Shanghai 200131 (CN). LI, Runyan; c/o WuXi Apptec Co., Ltd., 90 Delin Road Waigaoqiao, Free Trade Zone, Shanghai 200131 (CN).


(74) Agent: BELLOWS, Brent R. et al.; Knowles Intellectual

Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).


(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,


(54) Title: COMPOSITIONS AND DOSAGE FORMS FOR TREATMENT OF HPV INFECTION AND HPV-INDUCED NEOPLASIA



Compound I Monofumarate



Compound II



Compound III

FIG. 122

(57) Abstract: A pharmaceutically acceptable salt of an acyclic nucleotide phosphoramidate to treat HPV and related conditions including neoplasia, as well as pharmaceutical compositions, morphic forms and dosage forms thereof.

WO 2024/020127 A1

[Continued on next page]

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*